Over the past ten years tremendous progress has been achieved in corneal surgery. This volume - the 6th in the ESASO Course Series - reflects the most relevant topics ranging from basic knowledge to the most advanced techniques. It covers the functional anatomy with medical and surgical management of the ocular surface, provides information on high-risk corneal transplantation and explains techniques such as corneal collagen crosslinking, femtosecond laser-assisted penetrating deep anterior lamellar keratoplasty (DALK) and descemet membrane endothelial keratoplasty (DMEK). Further contributions describe how to manage astigmatism after corneal transplantation as well as indications of intrastroma corneal ring segments (ICRS) in keratoconus.

Well-known corneal and ocular surface surgeons and refractive surgery specialists share their experience in this publication, making it a must-read for every anterior segment surgeon, especially those performing corneal surgery and using corneal refractive procedures.
Ophthalmic Research

Journal for Translational and Clinical Research

Uwe Pleyer, Berlin (2003–2014); David E. Pelayes, Buenos Aires, Borja Corcóstegui,
Barcelona (2012–2014)

Editorial Board

Editor

José Cunha-Vaz, Coimbra

Associate Editors

Age-Related Macular Degeneration
José-Alain Sahel, Paris

Anterior Segment
Marie-José Tassignon, Antwerp

Epidemiology
Cécile Delcourt, Bordeaux

Genetics
Bart Leroy, Ghent

Glaucoma
M. Francesca Cordeiro, London

Health Technology
Francisco Batel Marques, Coimbra

Imaging
Tunde Peto, London

Immunology and Infectious Diseases
Dorairajan Balasubramanian, Hyderabad

Inflammation
José Manuel Benitez del Castillo, Madrid

Medical Retina
Sobha Sivaprasad, London

Molecular and Cell Biology
Francisco Ambrósio, Coimbra

Neuro-Ophthalmology and Visual Function
Birgit Lorenz, Giessen

Oncology and Pathology
Eduardo Midena, Padua

Surgery
Yuichiro Ogura, Nagoya

Educational – ESASO
Bruno Falcomatà, Reggio Calabria
Maurizio Battaglia Parodi, Milan

EVICR.net
Cecília Martinho, Coimbra

Editorial Board

J. Alio, Alicante
J. Ambati, Lexington, Ky.
A.J. Augustin, Karlsruhe
F. Bandello, Milan
A. Bringmann, Leipzig
T. Das, Hyderabad
D. Goldblum, Basel
G. Guarnaccia, Lugano
J. Hua, Boston, Mass.
T. Ishibashi, Fukuoka
J. Jonas, Mannheim
D. Lam, Guangzhou
C. Lobo, Coimbra
N. Osborne, Oxford

Y. Ozawa, Tokyo
M.J. Quadrado, Coimbra
M. Rehak, Berlin
G. Richard, Hamburg
S. Sarfare, Andover, Mass.
R.O. Schlingemann, Amsterdam
L. Schmetterer, Vienna
R. Silva, Coimbra
J. Smith, Adelaide, S.A.
P. Söderberg, Uppsala
J. Trevithick, London, Ont.
K. Tsubota, Tokyo
A. Wegener, Bonn

KARGER 125

Printed in Germany on acid-free and non-aging paper
(ISO 9706) by Stückle Druck, Ettenheim
Guidelines for Authors

Submission
Only original papers written in English are considered and should be submitted using the online submission website:

www.karger.com/ore

or as an e-mail attachment (the preferred word-processing package is MS-Word) to the Editorial Office:

Editorial Office Ophthalmic Research
S. Karger AG
P.O. Box
CH-4009 Basel (Switzerland)
Tel +41 61 306 1358
Fax +41 61 306 1434
E-Mail ore@karger.com

Types of Papers
(1) The main body of papers to be published will be "Original Papers" on experimental research. (2) "Review Papers" of up to 30 manuscript pages will be published from invited authors and by direct submission. In both cases the manuscripts will be subject to peer reviewing. Review papers will be published free of charge. (3) 'Mini Reviews' of up to 10 manuscript pages (double-spaced, including an abstract of max. 200 words and references) should contain an easy-to-read literature overview on a specific topic. Papers are either invited or may be submitted for consideration. Please submit your mini review online. (4) 'Short Communications' of up to 3–4 pages dealing with new original concepts or technical approaches will be published at short notice. (5) Ophthalmic Research has a tradition in publishing 'Supplements' which can be published under the responsibility of guest editors. Requests for such supplements should be addressed to the Editor-in-Chief.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication except in abstract form. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Ophthalmic Research and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. Research involving live human and animal subjects must have been approved by the author's institutional review board. Ophthalmic Research requires that in the Methods section of their manuscript the authors state that they adhered to the tenets of the Declaration of Helsinki or the NIH statement for the use of Animals in Research.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Arrangement
Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 200 words.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be sent in separate files. Tables require a heading and figures a legend, also in a separate file. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 225 mm). Black and white halftone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

Color Illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. (www.icmje.org).

Examples
(b) Papers published only withDOI numbers:
Theobaldes TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063585.
(d) Edited books:

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com
• Include the following statement:
  ‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author’s ChoiceSTM (Gold Open Access) articles, see Author’s ChoiceTM.
Author's Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/author_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement: 'The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].'

It is the author’s responsibility to fulfill these requirements.

Page Charges
There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 8 double-spaced manuscript pages (including abstract, tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

For over 40 years the Karger Gazette has been distributed to a growing audience worldwide. Published in newspaper format, it highlights advances in biomedicine and clinical practice, introduces personalities, portrays research institutes and chronicles milestones in the history of Karger Publishers in a lively and readable style.

The new anniversary issue celebrates Karger’s 125 years as a medical publisher. It explores the STM publishing business in the digital age, offers short portraits of Karger’s journal and book series editors, and includes interviews with three renowned scientists who talk about their careers and how they define progress.

Register for a free print subscription or read it online at www.karger.com/gazette
See the journal website for contents
16th ESASO
Retina Academy 2016
23 – 25 June 2016, Estoril/Portugal
The Journal of Innate Immunity is a bimonthly journal covering all aspects within the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of 'danger', microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies. The journal publishes original research articles, short communications, reviews, commentaries and letters to the editors. In addition to regular papers, some issues feature a special section with a thematic focus.

Selected contributions
- Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity: Kleinnijenhuis, J.; Quintin, J.; Preijers, F. (Nijmegen); Benn, C.S. (Copenhagen); Joosten, L.A.B.; Jacobs, C.; van Loenhout, J. (Nijmegen); Xavier, R.J. (Boston, Mass./Cambridge, Mass.); Aaby, P. (Copenhagen); van der Meer, J.W.M.; van Crevel, R.; Netea, M.G. (Nijmegen)
- Interferon-λ in the Context of Viral Infections: Production, Response and Therapeutic Implications: Hermant, P.; Michiels, T. (Brussels)
- The M1 Protein of Streptococcus pyogenes Triggers an Innate Uptake Mechanism into Polarized Human Endothelial Cells: Ochel, A.; Rohde, M.; Chhatwal, G.S.; Talay, S.R. (Braunschweig)
- Tissue-Specific Patterning of Host Innate Immune Responses by Staphylococcus aureus α-Toxin: Becker, R.E.N.; Berube, B.J.; Sampedro, G.R.; DeDent, A.C.; Bubeck Wardenburg, J. (Chicago, Ill.)
- M1 and M2 Macrophages: The Chicken and the Egg of Immunity: Mills, C.D. (Marine on St. Croix, Minn.); Ley, K. (La Jolla, Calif.)
Retinal Pharmacotherapeutics

Editors
Quan Dong Nguyen
Eduardo B. Rodrigues
Michel Eid Farah
William F. Mieler
Diana V. Do

Contents

Foreword: Miller, J.W.

Basic Sciences in the Retina
• Evolving Knowledge in Pharmacologic Treatments of Age-Related Macular Degeneration: Soubane Dagueg, G.; Risard-Gasiornovski, S.; Massamba, N.
• Retinal Anatomy and Pathology: Gupta, M.P.; Herzlich, A.A.; Sauers, T.; Chan, C.C.
• Retinal Biochemistry, Physiology and Cell Biology: Smith, R.L.; Saviprasad, S.; Chong, V.
• Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors: Rubino, R.G.; Adams, A.P.
• Ocular Immunity and Inflammation: Albini, T.A.; Davis, J.L.
• Complement Activation and Inhibition in Retinal Diseases: Kleinman, M.; Ambati, J.
• Genetics in Retinal Diseases: Riaz, M.; Baird, P.N.

Animal Models and Routes for Retinal Drug Delivery
• Routes for Drug Delivery to the Retina: Topical, Transscleral, Suprachoroidal and Intravitreal Gas Phase Delivery: Yamada, N.; Olsen, T.W.
• Routes for Drug Delivery: Sustained-Release Devices: Yun, S.; Huang, J.J.
• Microspheres and Nanotechnology for Drug Delivery: Johannesson, G.; Stefansson, E.; Lofstrand, T.
• Thermo-Responsive Hydrogels for Ocular Drug Delivery: Kang-Mieler, J.J.; Mieler, W.F.

Retinal Diseases Amenable to Pharmacotherapy
• Nonneovascular Age-Related Macular Degeneration: Michelis, S.; Garhofer, G.
• Neovascular Age-Related Macular Degeneration: Shaq, J.; Choudhary, M.M.; Schachat, A.P.
• Diabetic Retinopathy and Diabetic Macular Edema: Cohen, S.R.; Gardner, T.W.
• Retinal Vein Occlusion: Sawada, O.; Ohji, S.
• Retinal Detachment and Proliferative Veno-oculopathy: Kwon, O.W.; Song, J.H.; Roh, M.I.
• Posterior Vitreitis: Uy, H.S.; Yu-Keh, E.; Chan, P.S.
• Choroidal Neovascularization Secondary to Myopia, Infection, and Inflammation: Weber, M.L.; Heier, J.S.
• Treatment for Macular Telangiectasia Type 2: Charbel Issa, P.
• Neovascular Glaucma: Havens, S.J.; Gulati, V.
• Retinal Hereditary and Degenerative/Dystrophic Diseases (Non-Age-Related Macular Degeneration): Battaglia Parodi, M.; La Spina, C.; Corradetti, G.; Berichicci, L.; Petruzzi, G.; Bandello, F.

Drugs and Mechanisms in Retinal Diseases
• Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases: Rodrigues, E.B.; Farah, M.E.; Mantovani Bottos, J.; Bom Aggio, F.
• Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone: Cáceres-del-Carpio, J.; Donato Costa, R.; Haider, A.; Narayanan, R.; Kuppermann, B.D.
• Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab: Klein, A.; Loewenstein, A.
• Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab: Smith, A.G.; Kaiser, P.K.
• Biologic Therapies: Anti-Tumor Necrosis Factor-α, Anti-Interleukins, Rituximab and Others: Bhatt, N.; Tucker, W.; Sen, H.N.; Nussenblatt, R.B.
• Immunomodulatory Therapy in Uveitis: Tomkins-Netzer, O.; Talat, L.; Ismetova, F.; Samy, A.; Lightman, S.
• Sindulux for Retinal and Uveitic Diseases: Agarwal, A.; Rajagopalan, N.; Hassan, M.; Sadiq, M.A.; Soliman, M.K.; Afridi, R.; Sepah, V.J.; Nguyen, Q.D.
• The Protein Kinase C Inhibitor: Ruboxistaurin: Deissler, H.L.; Lang, G.E.
• Enzymustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy: Jack, L.S.; Sadiq, M.A.; Do, D.V.; Nguyen, Q.D.
• Ocular Gene Therapy: Campbell, J.P.; McFarland, T.J.; Stout, J.T.
• Retinal Neovascularization: Paulus, Y.M.; Campbell, J.P.
• Photosensitizers and Photodynamic Therapy: Verteporfin: Battaglia Parodi, M.; La Spina, C.; Berichicci, L.; Petruzzi, G.; Bandello, F.
• Chemotherapy for Malignant Intraocular Tumors: Shah, C.P.; Shields, C.L.; Shields, J.A.
• Antibiotics: Hapraprasad, S.M.; Mieler, W.F.

Pharmacotherapy and Surgery

• Enzymatic Vitrectomy and Pharmacologic Vitreodynamics: Shahr, A.R.; Trese, M.T.
• The Use of Vital Dyes during Vitreoretinal Surgery – Chromovitrectomy: Farah, M.E.; Maia, M.; Penha, F.M.; Rodrigues, E.B.

The Last Words

• Regulatory and Economic Considerations of Retinal Drugs: Shah, A.R.; Williams, G.A.
• Value-Based Medicine and Pharmacoeconomics: Brown, G.C.; Brown, M.M.
• Future Perspectives: Agents on the Horizon: Maya, J.R.; Sadiq, M.A.; Agarwal, A.; Kaiser, P.K.; Stoller, G.L.; Sepah, V.J.; Nguyen, Q.D.

The easiest way to order: www.karger.com/deoph
The last decade has observed significant progress in both basic and translational research, and in treatment options in the field of ocular oncology. Despite this, we are still seeking the ‘holy grail’ of effective therapeutics in disseminated ocular malignancies. We remain reliant on pre-clinical in vitro and in vivo models for testing drug efficacy.

Today, a range of animal models are available for studying ocular tumors, including uveal melanoma, conjunctival melanoma, retinoblastoma and vitreoretinal lymphoma. These models can also be used to determine how the host responds to tumors immunologically or to find out how certain genes or cytokines contribute to tumor growth.

Experts in the field of ocular oncology have contributed to this publication with a range of comprehensive reviews on the use of animal modeling for ocular tumors, including chick embryos, drosophila, zebrafish, mice, rats, rabbits and others. This volume will represent a useful background resource for researchers in the field.
Published since 1899, Ophthalmologica has become a frequently cited guide to international work in clinical and experimental ophthalmology. It contains a selection of patient-oriented contributions covering the etiology of eye diseases, diagnostic techniques, and advances in medical and surgical treatment, with special emphasis on retinal diseases. In addition to original papers, Ophthalmologica features regularly timely reviews in an effort to keep the reader well informed and updated. The large international circulation of this journal reflects its importance.

The open access journal Ophthalmologica Extra provides additional contents based on reviewed and accepted submissions to the main journal Ophthalmologica on www.karger.com/opx.

Ophthalmologica

New Editor 2015
S. Wolf, Bern

Associate Editors
J. Bainbridge, London
G. Coscas, Créteil
H. Heimann, Liverpool
J.-F. Korobelnik, Bordeaux
M. La Cour, Copenhagen

A. Loewenstein,
Tel-Aviv
Y. Ogura, Nagoya
R. Tadayoni, Paris
C. van Meurs, Rotterdam
M. Zinkernagel, Berne

The Official Journal of the
EURETINA

Selected contributions
- Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results: Freitas-da-Costa, P.; Pinheiro-Costa, J.; Carvalho, B.; Falcão, M.; Brandão, E.; Falcão-Reis, F.; Carneiro, A. (Porto)
- Central Serous Chorioretinopathy: Liegl, R.; Ulbig, M.W. (Munich)
- Role of Inflammation in Diabetic Macular Edema: Noma, H. (Hachioji/Yachiyo); Mimura, T. (Tokyo); Yasuda, K.; Shimura, M. (Hachioji)
- Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-Month Follow-Up and Prognostic Factors: Maggio, E.; Polito, A. (Negrar); Guerriero, M. (Verona); Pertile, G. (Negrar)
- Intravitreal Ranibizumab versus Isosmotic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial: Kreutzer, T.C. (Munich/Linz); Wolf, A. (Munich); Dirisamer, M.; Strauss, R.W. (Linz); Foerster, P. (Munich); Feltgen, N. (Göttingen); Pielen, A. (Fresburg); Hattenbach, L.-O. (Ludwigshafen); Kampik, A. (Munich); Priglinger, S.G. (Munich/Linz);
- Longitudinal Analysis of Reticular Drusen Associated with Age-Related Macular Degeneration Using Combined Confocal Scanning Laser Ophthalmoscopy and Spectral-Domain Optical Coherence Tomography Imaging: Steinberg, J.S.; Auge, J.; Fleckenstein, M.; Holz, F.G.; Schmitz-Valckenberg, S. (Bonn)
- Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study: Hatz, K. (Binningen/Liestal/Basel); Schneider, U.; Henrich, P.B.; Braun, B. (Basel); Sacu, S. (Vienna); Prünte, C. (Binningen/Liestal/Basel/Vienna)
- Stereotactic Radiotherapy for Polypoidal Choroidal Vasculopathy: A Pilot Study: Introini, U.; Casalino, G.; Triolo, G. (Milan); O’Shaughnessy, D.; Shusterman, E.M. (Newark, Calif.); Chakravarthy, U. (Belfast); Slakter, J.S. (New York, N.Y.); Bandello, F. (Milan)

More information at www.karger.com/oph

Impact Factor: 1.676
26 Metamorphopsia: An Overlooked Visual Symptom
Midena, E. (Padova/Rome); Vujosevic, S. (Padova)

Original Papers

1 Nornicotine and Nicotine Induced Neovascularization via Increased VEGF/PEDF Ratio
Zhang, Y.; Ma, A.; Wang, L.; Zhao, B. (Jinan)

10 Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome
Farinha, C.; Marques, J.P.; Almeida, E.; Baltar, A.; Santos, A.R.; Melo, P.; Costa, M.; Figueira, J.; Cachulo, M.L.; Pires, I.; Silva, R. (Coimbra)

19 Relevance of Retinal Thickness Changes in the OCT Inner and Outer Rings to Predict Progression to Clinical Macular Edema: An Attempt of Composite Grading of Macular Edema
Vujosevic, S. (Padova); Varano, M. (Rome); Egan, C.; Sivaprasad, S. (London); Menon, G. (Frimley); Erginay, A. (Paris); Verbraak, F.D. (Amsterdam); Lund-Andersen, H. (Glostrup); Martinez, J.P. (Rotterdam); Jürgens, I. (Barcelona); Smets, E. (Antwerp); Coriat, C. (Paris); Wiedemann, P. (Leipzig); Ágoas, V. (Lisboa); Querques, G. (Créteil); Holz, F.G. (Bonn); Nunes, S.; Alves, D.; Neves, C.; Santos, T.; Ribeiro, L. (Coimbra); Bandello, F. (Milan); Tejerina, A.N. (Valencia); Cunha-Vaz, J. (Coimbra) for the EVICR.net

37 Expression of Vascular Endothelial Growth Factor by Retinal Pigment Epithelial Cells Induced by Amyloid-β Is Depressed by an Endoplasmic Reticulum Stress Inhibitor

45 Autologous Internal Limiting Membrane Fragment Transplantation for Large, Chronic, and Refractory Macular Holes
De Novelli, F.J.; Preti, R.C.; Ribeiro Monteiro, M.L. (São Paulo); Pelayes, D.E. (Buenos Aires); Junqueira Nóbrega, M. (Joinville); Takahashi, W.Y. (São Paulo)